Biogen stock plummets after it abandons Alzheimer's drug
At the opening bell, Biogen Inc. lost more than $16 billion in market value after disclosing it would scrap its most advanced Alzheimer's disease drug candidate. Cambridge-based Bi…
At the opening bell, Biogen Inc. lost more than $16 billion in market value after disclosing it would scrap its most advanced Alzheimer's disease drug candidate. Cambridge-based Bi…